GENE ONLINE|News &
Opinion
Blog

2025-12-02|

Study Explores Impact of Volume-Controlled Ventilation on Carbon Dioxide Retention in Newborns During Transport

by GOAI
Share To

A recent study published in *Pediatric Research* on December 2, 2025, examines the effects of volume-controlled versus non-volume-controlled ventilation on carbon dioxide retention in newborns during transport. Researchers Leslie, Davidson, Forshaw, and their team conducted the investigation to address critical concerns surrounding neonatal respiratory care. The study provides comparative data on how these two ventilation methods impact CO₂ levels in neonates, a key factor in ensuring effective respiratory support.

The research highlights the differences between volume-controlled ventilation (VCV) and non-volume-controlled ventilation (NVCV), focusing specifically on their ability to manage carbon dioxide levels during neonatal transport. Neonatal transport often presents unique challenges due to the delicate nature of newborns’ respiratory systems and the need for precise interventions. By analyzing outcomes related to CO₂ retention under both methods, the study aims to inform clinical practices and improve care strategies for this vulnerable population. Further details about methodology and specific findings were not disclosed in the initial report but are available through the publication in *Pediatric Research*.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

For any suggestion and feedback, please contact us.

Date: December 2, 2025

©www.geneonline.com All rights reserved. Collaborate with us: [email protected]
Author
Related Post
Taiwan Healthcare Expo Opens With €200 Million Czech Deal as Global Buyers Flock to Taipei
2025-12-07
LATEST
Taiwan Healthcare Expo Opens With €200 Million Czech Deal as Global Buyers Flock to Taipei
2025-12-07
AI-Driven Healthcare Transformation at Healthcare Expo Taiwan 2025
2025-12-05
How AWS Cloud Is Transforming Global Smart Healthcare and Trusted Research Environments
2025-12-03
MedTex 2025: Taiwan as Gateway for AI-Driven Medical Innovation and Global Capital
2025-12-03
FDA CBER Director Vinay Prasad Issues November 2025 Memo Addressing Vaccine Development and Regulatory Challenges
2025-12-03
FDA to Review 16 Drug Applications Including 8 New Molecular Entities by Year-End
2025-12-03
Stephen Durso Named CEO of Altimmune Inc. as Vipin Garg Steps Down
2025-12-03
EVENT
2025-12-06
The 67th ASH Annual Meeting and Exposition
Orlando, Florida, USA
Scroll to Top